| Document |
Document Title |
|
WO/2005/068432A1 |
The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represen...
|
|
WO/2005/067933A1 |
The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z ...
|
|
WO/2005/068445A2 |
The invention relates to compounds of formula (I) wherein Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or taut...
|
|
WO/2005/066114A1 |
The present invention relates to cornpounds of the formula (I) or (II) or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing.
|
|
WO/2005/065779A1 |
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment usin...
|
|
WO/2005/066145A1 |
This invention relates to compounds that are of formula (I) wherein A is heteroaryl and R1 and R2 are both cyclic residues, that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct trea...
|
|
WO/2005/065683A1 |
The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is...
|
|
WO/2005/066147A1 |
Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, ami...
|
|
WO/2005/061465A1 |
The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are each hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hy...
|
|
WO/2005/061477A1 |
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors: Formule (I).
|
|
WO/2005/058808A1 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-...
|
|
WO/2005/058848A1 |
The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activit...
|
|
WO/2005/057171A2 |
The present invention relates to 1,4-disubstituted naphthalene scaffold compounds and other closely related scaffold compounds. The present invention also relates to combinatorial libraries of such compounds. In addition, the present inv...
|
|
WO/2005/055715A2 |
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U...
|
|
WO/2005/054430A2 |
Hepatitis C virus inhibitors are disclosed having the general formula: (I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are ...
|
|
WO/2005/054218A1 |
The present invention relates to β-adrenergic blockers nitrooxyderivatives of general formula (I): A-(Y-ONO2)s and enantiomers and diastereoisomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing th...
|
|
WO/2005/051932A1 |
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...
|
|
WO/2005/049546A1 |
A halogenated bisdiarylaminopolycyclic aromatic compound, polymers made therefrom, and polymeric light emitting diode devices using the polymers are described. The halogenated compound is represented by formula (I), wherein Ar and Ar' ar...
|
|
WO/2005/041959A1 |
The invention features phenoxyacetic acids and analogs of formula (I), compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2005/042493A1 |
The invention relates to novel hexyl carboxanilides of formula (I), in which L, R1, R3 and A are defined as cited in the description, to several methods for producing said substances, to their use for controlling undesirable micro-organi...
|
|
WO/2005/040101A1 |
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These c...
|
|
WO/2005/040100A1 |
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...
|
|
WO/2005/037805A2 |
The present invention relates to a 1,2,4-thiadiazole compound of the formula (I) represented by the formula (1): wherein R¿1? represents C3-C7 alkynyl and X represents C4-C7 straight alkylene optionally substituted with one to four of R...
|
|
WO/2005/037844A1 |
The inVention is related to new substituted phenyl fused heterocycle compounds having herbicidal activities, these compounds are characterized by high efficiency, low toxicity, high selectivity, and the like.
|
|
WO/2005/035512A1 |
Antitumor agents containing as the active ingredient thiadiazoline derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein Z is sulfur or the like; R1 is substituted or unsubstituted ...
|
|
WO/2005/030736A1 |
A description follows of 1,3-diones having general formula (I): together with their use as herbicides for the control of weeds in agricultural crops.
|
|
WO2005007636B1 |
The invention relates to methods for the production and use of novel 1,2,4-thiadiazols of general formulae (I) or (II) as agents for regulating the inhibition of enzymatic urea hydrolysis, wherein R<1> = hydrogen, C1-C8-alkyl or C6-C10-a...
|
|
WO/2005/026139A1 |
The invention relates to a compound of the formula (I) wherein R represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkylthioalkyl, haloalkyl, alkoxy, alkylthio, represents optionally substituted phenyl or benzyl, or represent...
|
|
WO/2005/025293A2 |
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazoli...
|
|
WO/2005/023183A2 |
The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionall...
|
|
WO/2005/023182A2 |
The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, an...
|
|
WO2004074270B1 |
The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R<1> and R<2>, are as defined herein. The invention also relates to methods of trea...
|
|
WO/2005/021490A2 |
The invention relates to N-sulfonyl-&agr -amino-acetic acid derivatives of the general formula (I): including the optical isomers thereof and mixtures of such isomers, wherein Ar1 and Ar2 independently of each other stand for an optional...
|
|
WO/2005/020991A1 |
The present invention relates to compounds of the Formula; wherein R3, R5, R7, U, X, Y and Z are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical com...
|
|
WO/2005/021520A1 |
The invention relates to novel 1,2,4-thiadiazoles of formula (I), in which R1, R2, R3, R4, R5, R6 and A are defined as cited in the description, to methods for producing said compounds and to their use in controlling undesired micro-orga...
|
|
WO/2005/019191A2 |
Compounds having the formula (I), wherein B is (a), (b), (c), or (d); A is a monocyclic or bicyclic ring selected from the group consisting of aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocycle (the other substituents are defined...
|
|
WO/2005/019212A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019184A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019192A1 |
The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/016911A1 |
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula (I), wherein the substituents are as described herein.
|
|
WO/2005/013914A2 |
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...
|
|
WO/2005/012275A2 |
Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/005374A1 |
The present invention provides compounds having the formula: (I) wherein R1, R', R2, R3, R3’, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting p...
|
|
WO/2005/006807A1 |
A wireless microphone communication system (1) comprises a wireless microphone transmitter (91b) and a wireless microphone receiver (11). The wireless microphone transmitter (91b) includes an infrared interface (91c), a control part (91d...
|
|
WO/2005/005395A2 |
Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherei...
|
|
WO/2005/006806A1 |
A wireless microphone communication system (1) comprises one or more control apparatuses (21-24) having LAN interfaces; and one or more receiver apparatuses (11-18) having LAN interfaces for receiving radio waves from the transmitter of ...
|
|
WO/2005/003106A1 |
The present invention relates to macrocyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, p...
|
|
WO/2005/000309A2 |
Compounds of the formulae (I) and (II), and pharmaceutically acceptable salts thereof, are found to be inhibitors of sensory neurone specific (SNS) sodium channels. They are therefore useful as analgesic and neuroprotective agents. Formu...
|
